UBS Group’s Lexaria Bioscience Warrant LEXXW Stock Holding History

UBS Group’s Portfolio LEXXW Stock Details LEXXW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,424	Closed	-$194	–	10897
2025 Q3	$194	Sell	2,424 -1,771	-42%	-$208	﹤0.01%	9824
2025 Q2	$420	Hold	4,195	–	–	﹤0.01%	9834
2025 Q1	$1.58K	Sell	4,195 -984	-19%	-$380	﹤0.01%	9486
2024 Q4	$4.2K	Sell	5,179 -22,886	-82%	-$17.8K	﹤0.01%	8776
2024 Q3	$25.8K	Sell	28,065 -65,657	-70%	-$75.6K	﹤0.01%	7215
2024 Q2	$75.5K	Buy	93,722 +93,623	+94,569%	+$106K	﹤0.01%	6374
2024 Q1	$149	Buy	+99	New	+$94	﹤0.01%	8777
2023 Q4	–	Sell	-122	Closed	-$24	–	9636
2023 Q3	$24	Sell	122 -251	-67%	-$60	﹤0.01%	9098
2023 Q2	$82	Buy	+373	New	+$129	﹤0.01%	8541
2022 Q3	–	Sell	-1,061	Closed	-$1K	–	10656
2022 Q2	$1K	Buy	+1,061	New	+$930	﹤0.01%	9896
2022 Q1	–	Sell	-784	Closed	-$1K	–	10608
2021 Q4	$1K	Buy	+784	New	+$1.53K	﹤0.01%	9995

Other funds holding LEXXW

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

UBS Group's LEXXW Position: Q4 2025 in Review

UBS Group sold out of Lexaria Bioscience Warrant (LEXXW) in Q4 2025, closing a stake of 2,424 shares — an estimated $194 sold.

UBS Group first reported a position in LEXXW in Q4 2021 and held it in 11 quarters. The position peaked at $75.5K in Q2 2024. 3 funds tracked by Wall St. Rank hold LEXXW as of Q4 2025.

UBS Group reported no remaining Lexaria Bioscience Warrant position as of Q4 2025 after selling out during the quarter.
UBS Group sold 2,424 Lexaria Bioscience Warrant shares in Q4 2025, an estimated $194.
UBS Group first reported a position in Lexaria Bioscience Warrant in Q4 2021 and held it in 11 quarters.
UBS Group's Lexaria Bioscience Warrant position peaked at $75.5K in Q2 2024.
3 funds tracked by Wall St. Rank held Lexaria Bioscience Warrant as of Q4 2025.

Based on UBS Group's 13F filing for Q4 2025, filed 29 Jan 2026.